U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945146) titled 'Genomics Study in CML Patients With Ponatinib Treatment' on April 18.
Brief Summary: This study will evaluate whether responsiveness and adverse events (AEs) to second-line or later ponatinib treatment are associated with genetic variations as measured by real-time quantitative polymerase chain reaction (qRT-PCR) and next-generation sequencing (NGS) in patients with CML of any stage who failed prior multiple targeted therapies except ponatinib.
Study Start Date: Sept. 01, 2020
Study Type: OBSERVATIONAL
Condition:
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Intervention:
DRUG: Ponatinib
Ponatinib treatment will be initiat...